Does Mounjaro Stop Working After a While — or Does Something Else Explain It?

The biggest misconception: a plateau is not the medicine failing

Most people ask whether Mounjaro stops working after a while because their weekly losses have stalled. This is almost always a normal metabolic event, not a pharmaceutical one. As body weight falls, your resting energy requirement shrinks alongside it. The same calorie deficit that produced steady losses at the start of treatment becomes a smaller percentage gap at a lower body weight. The medicine is still activating GIP and GLP-1 receptors, still slowing gastric emptying, still reducing appetite, the biology of weight loss itself is working against continued rapid progress.

Clinical trials are instructive here. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that average weight reduction in participants at the highest dose reached around 20–21% over 72 weeks, but that loss was not linear. The rate of reduction typically slows in the second half of treatment as participants approach a new set point. That curve is evidence of normal physiology, not of the medicine running out of effect.

What genuinely helps at a plateau is a review of protein intake, activity levels and sleep. Muscle tissue is metabolically expensive to maintain; losing it during rapid weight loss slows your baseline energy burn further. A prescriber can also assess whether a dose increase is appropriate, many patients plateau at an intermediate dose and find loss resumes at a higher one. You can read more about the broader question of what to do when Mounjaro seems to stop working in detail.

When tirzepatide's effect can genuinely decline

There is a smaller and more specific question buried inside the plateau one: can tirzepatide's pharmacological response weaken in some patients over time? The honest answer is yes, in certain circumstances.

The first and most common is subtherapeutic dosing. The 2.5mg starting pen exists so your body tolerates the medicine, the prescriber titrates upward over weeks. Patients who remain at a low dose for longer than intended, or who miss multiple injections, may find the appetite-suppressing effect feels weaker. Consistency matters. For practical reasons of habit, keeping the pen in the fridge door (somewhere you open every morning anyway) is the kind of routine that prevents accidental skips.

The second situation is true secondary failure. In some patients, GLP-1 and GIP receptor sensitivity may reduce over a prolonged period, particularly if weight has been largely stable for many months. This is relatively uncommon and requires proper clinical assessment before drawing any conclusions. An in-depth look at secondary failure and plateau patterns covers the distinction carefully.

Third, there is the question of lifestyle drift. Tirzepatide's effect on appetite does a lot of heavy lifting early in treatment; over time, as higher-calorie eating habits reassert themselves (sometimes subtly), the medicine's net contribution to the deficit narrows. This is not failure, it is a prompt to revisit diet and activity with a professional.

A related concern some readers arrive with is whether tirzepatide interacts with their other medicines in ways that affect weight loss. The question of Mounjaro alongside anticoagulants like rivaroxaban is one worth raising with your prescriber if it applies to you.

Does the same pattern apply to the oral GLP-1 medicines, and where does this leave long-term treatment?

The same metabolic plateau logic applies to all GLP-1 receptor agonists, including semaglutide. If you are asking whether tirzepatide specifically stops working versus whether this is a GLP-1 class effect, the evidence points to the latter, plateau is biology, not brand. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if less than 5% weight loss has been achieved after six months at the highest tolerated dose, which is the clinical anchor for assessing genuine non-response rather than a normal plateau.

Long-term treatment is the subject of ongoing research. What the current data show clearly is that weight tends to return after stopping, which means that for most people, these medicines work best as part of a sustained plan rather than a short course. That plan includes the prescriber-led reviews that happen before every repeat with a regulated service, there are no automatic refills, because each re-prescription is an opportunity to check that treatment is still the right choice and that it is working as it should. You can explore the full picture of what tirzepatide treatment involves, and what the evidence says about longer-term outcomes, before deciding whether to start. The cost context for Mounjaro is also worth reading alongside this, since pricing has shifted significantly since 2025.

One practical note on contraception: if you take a combined oral contraceptive pill, NHS guidance advises adding a non-oral method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because absorption of the pill may be reduced. This is unrelated to weight loss but important enough to act on. More detail is at Mounjaro and the contraceptive pill.